Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 211 bp insertion in exon1 and 82 bp insertion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-RANBP2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RanBP2 also known as Nucleoporin 358 (Nup358) is a large protein with a molecular mass of approximately 358 kDa. It is an important component of the nuclear pore complex (NPC) and is found on the cytoplasmic side of the nuclear envelope. RanBP2 is expressed in a variety of tissues with higher levels in the brain and testis. Its alternates names include Nup358 due to its role as a nucleoporin. Mechanically RanBP2 facilitates nucleocytoplasmic transport by interacting with the small GTPase Ran.
Biological function summary
RanBP2 plays a significant role in multiple processes such as mitotic spindle assembly and chromatin condensation. It functions as part of the Ran GTPase system a critical complex for nucleocytoplasmic transport. In addition RanBP2 contributes to protein sumoylation where it acts as a scaffold for conjugating enzymes. It maintains nuclear envelope integrity and supports the positioning of centrosomes during cell division.
Pathways
RanBP2 is actively involved in the nucleocytoplasmic transport pathway ensuring the proper exchange of proteins and RNA between the nucleus and cytoplasm. It is critical to the Ran cycle where it works alongside proteins like RanGTP and RanGAP1 to regulate transport activities. The involvement of RanBP2 in the SUMOylation pathway also emphasizes its role in post-translational modification impacting various cellular events and signaling.
Changes in RanBP2 expression have been linked to neurodegenerative diseases and certain types of cancer. In neurodegenerative conditions such as hereditary spastic paraplegia RanBP2 forms a complex with proteins like atlastin-1 which further influences disease progression. In cancer RanBP2 interacts with oncogenic pathways through its role in cell cycle regulation highlighting its potential as a therapeutic target.
